# Body Composition Analyzers Market

> Body Composition Analyzers Market Research Report: Size, Share, Trend Analysis By Applications (Fitness Centers, Healthcare, Sports Organizations, Research Institutions), By Product Type (Bioelectrical Impedance Analysis Devices, Dual-Energy X-ray Absorptiometry Devices, Infrared Body Composition Analyzers, Skinfold Calipers), By End Users (Individuals, Clinics, Gyms and Fitness Centers, Hospitals, Sports Teams), By Distribution Channel (Online Retail, Offline Retail, Direct Sales) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.0%
- **2025:** USD 684.2 Million
- **2035:** USD 1,225.4 Million
- **Key Players:** InBody, Tanita, seca, GE HealthCare, Hologic Inc., Omron Healthcare, Withings, COSMED S.r.l.

**Report ID:** MRFR/HC/7001-HCR · **Pages:** 105 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** October 28, 2026

**URL:** https://www.marketresearchfuture.com/reports/body-composition-analyzers-market-8473

---

## Market Summary

As per MRFR analysis, the Body Composition Analyzers Market size was valued at USD 4.356 Billion in 2024. The market is projected to grow from USD 4.662 Billion in 2025 to USD 9.197 Billion by 2035, exhibiting a CAGR of 7.03% during the forecast period 2025-2035. North America led the market with over 39.03% share, generating around USD 1.7 billion in revenue.
 
The Body Composition Analyzers Market is driven by rising global health consciousness, increasing prevalence of obesity and lifestyle diseases, and growing preventive healthcare adoption. Key trends include rapid technological advancements (smart, connected devices with improved accuracy), integration with fitness ecosystems, and expanding use across clinical, fitness, and home settings, fueling strong market growth.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising obesity and metabolic disease prevalence | +1.4% | Global | Long-term (≥4 yr) | [1] |
| Multi-frequency BIA accuracy gains | +1.0% | North America, Europe, Asia-Pacific | Medium-term (2–4 yr) | [5] |
| Remote patient monitoring reimbursement | +0.9% | North America | Short-term (≤2 yr) | [7] |
| Aging populations and sarcopenia screening | +0.8% | Japan, Europe, North America | Long-term (≥4 yr) | [4][15] |
| GLP-1 therapy uptake and lean-mass monitoring | +0.7% | North America, Europe | Short-term (≤2 yr) | [24] |
| National preventive-health and fitness programs | +0.6% | Asia-Pacific | Medium-term (2–4 yr) | [11] |

### Rising Obesity and Metabolic Disease Prevalence

Obesity is the single largest demand base. The WHO estimates that 890 million adults were living with obesity in 2022 [1]. The IDF expects adult diabetes cases to rise from 537 million in 2021 to 783 million by 2045. BMI misclassifies muscular and sarcopenic patients, so clinicians managing these populations increasingly want compartment-level fat and muscle data. That preference sustains purchasing across endocrinology, bariatric, and primary-care settings.

### Multi-frequency BIA Accuracy Gains

Multi-frequency current injection, typically spanning 5 kHz to 1,000 kHz, lets analyzers estimate total body water and its intracellular and extracellular fractions separately [5]. This narrows the accuracy gap with reference methods while keeping test times under a minute and avoiding radiation. Hospitals that once reserved composition testing for DXA suites can now run bedside fluid assessments, which expands the number of clinical departments buying analyzers.

### Remote Patient Monitoring Reimbursement

CMS rules pay for remote physiologic monitoring when a device transmits data on at least 16 days in 30 days, under CPT 99454 [7]. The CY2025 Physician Fee Schedule kept these codes in place, preserving the revenue case for prescribing connected scales to patients with heart failure, chronic kidney disease, or obesity. Device vendors with FDA-registered, cellular-enabled scales capture the largest share of this channel.

### Aging Populations and Sarcopenia Screening

The UN projects the share of people aged 65 and over will rise from 10% in 2022 to 16% by 2050 [4]. EWGSOP2 guidance makes low muscle quantity a confirmatory criterion for sarcopenia, and it names BIA and DXA as acceptable measurement tools [15]. Geriatric clinics, rehabilitation centers, and long-term care operators are therefore budgeting for analyzers as standard assessment equipment.

### GLP-1 Therapy Uptake and Lean-Mass Monitoring

In the STEP 1 trial, DXA sub-analysis showed that lean tissue accounted for close to two-fifths of total weight lost on semaglutide [24]. With tirzepatide approved for chronic [weight management](https://www.marketresearchfuture.com/reports/weight-management-market-19222) in November 2023, obesity clinics now track muscle preservation alongside weight loss. Routine follow-up measurement creates repeat-test demand, favoring fast and affordable impedance systems.

### National Preventive-Health and Fitness Programs

Japan's Specific Health Checkups screen adults aged 40–74 for metabolic syndrome every year [11]. China's Healthy China Action sets explicit population fitness targets through 2030, and India's Fit India Movement promotes fitness assessment in schools and workplaces. These programs generate institutional procurement and raise consumer awareness, accelerating adoption across Asia-Pacific.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on the Body Composition Analyzers Market growth rate. They are not additive and partly offset one another across regions and timeframes.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of DEXA and plethysmography systems | −0.6% | Emerging markets, smaller clinics | Long-term (≥4 yr) | [19][20] |
| Measurement variability in consumer devices | −0.5% | Global | Medium-term (2–4 yr) | [5] |
| Limited reimbursement for composition testing | −0.4% | North America, Europe | Medium-term (2–4 yr) | [7] |
| EU MDR compliance costs | −0.3% | Europe | Short-term (≤2 yr) | [9][10] |
| Health-data privacy and cybersecurity requirements | −0.3% | Global | Medium-term (2–4 yr) | [22][23] |

### High Capital Cost of DEXA and Plethysmography Systems

Reference-grade systems require shielded rooms, licensed operators, and capital budgets that most community clinics cannot justify. A DEXA body composition scan also carries radiation-protocol requirements under national safety rules, which limits repeat testing [20]. Air-displacement units add space and calibration demands. Together, these barriers confine gold-standard methods to tertiary hospitals and research centers.

### Measurement Variability in Consumer Devices

Hydration, recent meals, skin temperature and electrode contact influence impedance values [5]. Low-cost foot-to-foot scales use demographic equations that may be inappropriate for geriatric, pediatric or ethnically diverse users. Inconsistent findings undermine clinical confidence in home data and hinder the inclusion of consumer devices into formal care pathways.

### Limited Reimbursement for Composition Testing

Reimbursement for standalone body composition testing is limited outside of remote monitoring schemes [7]. Clinics must therefore either bill packaged visits for testing costs or bill patients directly. This limits volume in primary care, especially in European public systems because tariff schedules rarely allow billing for composition analysis.

### EU MDR Compliance Costs

Regulation (EU) 2017/745 raised clinical-evidence and post-market surveillance requirements for medical devices [9]. Regulation (EU) 2023/607 extended transition deadlines to 2027–2028 [10], but notified-body capacity remains tight. Smaller manufacturers face certification costs that can delay launches or push them to withdraw legacy product lines from the European market.

### Health-Data Privacy and Cybersecurity Requirements

Analyzers connected to the cloud process sensitive health data protected by the GDPR, which authorizes fines up to 4% of the worldwide annual turnover [22], and the HIPAA security rule in the United States [23]. More and more hospital tenders involve penetration testing and security certification. This increases sales cycles and development expenses for connected platforms.

## Opportunities

## Body Composition Analyzers Market Opportunities

### Muscle-Health Programs in GLP-1 Obesity Care

Incretin treatments prescribed by obesity clinics require repeatable, low-cost lean-mass tracking at every follow-up visit [24]. Vendors integrating protocol software, resistance training cues, physician dashboards and analyzers may ensure recurring placements across clinical channels of the Body Composition Analyzers Market. Segmental and multi-frequency platforms are well positioned to cater to this need.

### Underpenetrated Demand in India and Brazil

India's fitness-assessment push and Brazil's large private gym and clinic networks offer volume growth that mature markets cannot match. Mid-priced, ruggedized portable analyzers with localized equations and regional-language interfaces can close the gap between premium imports and unvalidated low-end devices.

### Data Monetization and Subscription Analytics

Cloud platforms that aggregate anonymized readings can provide cohort benchmarking to employers, insurers, and research sponsors. Vendors such as InBody already sell dashboard analytics alongside hardware [16]. Moving from one-time device sales to per-test or per-site subscriptions smooths revenue and deepens customer lock-in.

### Smartphone-Based 3-D Optical Assessment

Computer-vision models can now estimate body shape and composition from smartphone images without dedicated hardware. Asset-light partnerships between scanning-software firms and fitness apps let vendors reach consumers at near-zero marginal cost. Well-funded entrants such as Neko Health show investor appetite for camera-based screening.

### Phase-Angle Analytics in Oncology and Critical Care

Phase angle is gaining traction as a prognostic marker for malnutrition and treatment tolerance. Oncology and intensive-care units can use it to guide nutrition support and chemotherapy dosing decisions [5]. Vendors that validate phase-angle software for these settings can open hospital budgets that sit outside traditional nutrition departments.

## Future Outlook

## Body Composition Analyzers Market Future Outlook

### AI-Calibrated Equations and Bias Reduction

Machine-learning models trained on paired impedance and DXA datasets will replace fixed population equations. They will adjust estimates for age, ethnicity, and disease state. This shift addresses the accuracy criticism that has held back clinical acceptance [5]. By the early 2030s, regulators are likely to expect documented algorithm-performance audits for clinical-grade devices.

### Platform Economics and Recurring Revenue

Hardware margins will narrow as optical and smartphone methods commoditize basic measurement. Value in the Body Composition Analyzers Market will move toward cloud analytics, coaching software, and EHR integration billed by subscription. Vendors with large installed bases and open APIs will benefit most from this transition [16].

### Muscle-Centric Medicine

Population aging and incretin-based obesity treatment are making muscle mass a vital sign. With people aged 65 and over set to make up 16% of the global population by 2050 [4] and 2.5 billion adults overweight [1], health systems will screen muscle as routinely as blood pressure. That shift will sustain demand for fast, repeatable measurement.

### Interoperability and Data Governance

Hospitals will require analyzers to export structured data through HL7 FHIR interfaces and to meet GDPR and HIPAA safeguards [22][23]. Interoperability will become a tender requirement rather than a differentiator. Vendors that certify security early will gain access to integrated care networks and national digital-health programs.

## Segment Insights

## Body Composition Analyzers Market Segmentation

The Body Composition Analyzers Market is segmented by product, measurement technology, and end user. The regional view is covered in Section 7.

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Bio-impedance Analyzers | 46.9% share (2025) | Clinical validation, moderate cost |
| Skinfold Calipers | USD 21.6 Million (2025) | Education and field assessment |
| Hydrostatic Weighing Equipment | 2.8% share (2025) | Research reference testing |
| Air-Displacement Plethysmography | 4.9% CAGR (2026–2035) | Pediatric and research accuracy |
| Dual-energy X-ray Absorptiometry (DEXA) | USD 108.4 Million (2025) | Osteoporosis and research workflows |
| 3-D Optical Body Scanners | 7.7% CAGR (2026–2035) | Computer vision, falling hardware cost |
| Smart Connected Scales | 12.6% share (2025) | Home wellness and RPM |
| Other Products | USD 15.2 Million (2025) | Niche clinical tools |

Bio-impedance Analyzers lead the Body Composition Analyzers Market by product because they combine validated accuracy, fast tests, and no radiation at a price clinics can absorb. 3-D Optical Body Scanners grow fastest as computer-vision algorithms mature and fitness chains adopt shape-tracking visuals. Dual-energy X-ray Absorptiometry (DEXA) remains the research reference, Smart Connected Scales serve home users, and Skinfold Calipers, Hydrostatic Weighing Equipment, and Air-Displacement Plethysmography retain education and research niches.

### By Measurement Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Single-frequency BIA | 12.4% share (2025) | Budget-limited settings |
| Multi-frequency BIA | 57.1% share (2025) | Fluid-compartment accuracy |
| Segmental BIA | USD 63.0 Million (2025) | Limb-level rehabilitation analysis |
| Portable/Hand-held Systems | 8.6% CAGR (2026–2035) | Primary care and home visits |
| Benchtop/Standalone Systems | USD 69.8 Million (2025) | Tertiary hospitals, EMR integration |

Within the Body Composition Analyzers Market, Multi-frequency BIA leads because separating intracellular from extracellular water supports dialysis, oncology, and critical-care decisions. Portable/Hand-held Systems grow fastest as primary-care physicians and visiting nurses adopt lightweight devices that sync with mobile dashboards. Segmental BIA supports rehabilitation, while Benchtop/Standalone Systems serve hospitals that need full fat-free mass measurement and EMR integration. Single-frequency BIA continues to lose share as prices for multi-frequency units fall.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | 38.9% share (2025) | Bariatric, renal, and oncology care |
| Sports Medicine Centers | USD 158.1 Million (2025) | Athlete load and recovery monitoring |
| Home Care Settings | 9.0% CAGR (2026–2035) | Telehealth and RPM reimbursement |
| Academic & Research Institutes | 14.6% share (2025) | Validation trials and methodology studies |

Hospitals & Clinics hold the largest share of the Body Composition Analyzers Market by end user, where impedance-derived fluid data guide dialysis management and chemotherapy dosing. Home Care Settings grow fastest as connected scales push encrypted readings to dietitians and qualify for remote monitoring reimbursement. Sports Medicine Centers use segmental units to tune training loads. Academic & Research Institutes run validation studies that shape next-generation equations.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.4% share | RPM reimbursement, GLP-1 clinic monitoring, bariatric care |
| Europe | USD 188.8 Million | Sarcopenia screening, NHS weight programs, MDR-compliant upgrades |
| Asia-Pacific | 7.9% CAGR (2026–2035) | Metabolic checkups, fitness programs, local manufacturing |
| South America | 5.3% share | Private gym chains, aesthetic and nutrition clinics |
| Middle East & Africa | USD 31.5 Million | Diabetes care, premium wellness centers |
| Total | USD 684.2 Million | — |

The Body Composition Analyzers Market shows clear regional tiers. Mature reimbursement-driven demand in North America and Europe contrasts with program-led expansion across Asia-Pacific.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 84.2% of regional share | RPM codes, obesity prevalence, GLP-1 clinics |
| Canada | 6.4% CAGR (2026–2035) | Provincial chronic-disease programs |
| Mexico | USD 14.7 Million | High diabetes burden, private clinic growth |

The United States dominates regional revenue. Adult obesity prevalence reached 40.3% in the August 2021–August 2023 survey period [6], and CMS remote monitoring codes reimburse connected-device programs [7]. Most consumer body fat scales are marketed as Class II devices exempt from premarket notification under FDA product classifications [8], which keeps launch costs low. Canada's growth follows provincial investment in chronic-disease management, while Mexico's demand comes from private clinics serving diabetic patients.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.6% of regional share | Hospital nutrition screening, domestic manufacturing |
| United Kingdom | USD 36.1 Million | NHS Digital Weight Management Programme |
| France | 5.9% CAGR (2026–2035) | Geriatric care and sarcopenia assessment |
| Italy | 12.3% of regional share | Sports medicine and rehabilitation |
| Spain | USD 15.8 Million | Private nutrition clinics |
| Rest of Europe | 21.4% of regional share | Public-hospital modernization |

Germany anchors European demand through hospital malnutrition screening and a strong domestic manufacturer base. The United Kingdom's digital weight-management referrals [14] support connected-scale uptake. France and Italy rely on geriatric and sports-medicine demand shaped by EWGSOP2 guidance [15]. MDR certification remains the main purchasing filter across the region, and it favors established vendors with complete technical files [9].

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 33.8% of regional share | Healthy China Action, domestic production |
| Japan | USD 37.6 Million | Specific Health Checkups, aging population |
| India | 10.2% CAGR (2026–2035) | Fit India Movement, urban fitness boom |
| Australia | 8.9% of regional share | Sports science and allied health |
| South Korea | USD 12.9 Million | Home of leading device makers, wellness culture |
| Rest of Asia-Pacific | 8.3% CAGR (2026–2035) | Medical tourism and private hospitals |

Asia-Pacific is the fastest-growing region in the Body Composition Analyzers Market. Japan's mandatory metabolic checkups for adults aged 40–74 [11] support a dense installed base. China's Healthy China Action drives provincial hospital procurement and competitive local manufacturing. India grows fastest at the country level as gyms, corporate wellness programs, and diagnostic chains adopt portable analyzers.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.2% of regional share | Large gym networks, aesthetic medicine |
| Argentina | USD 6.9 Million | Sports nutrition and clinical dietetics |
| Rest of South America | 5.8% CAGR (2026–2035) | Private hospital expansion |

Brazil accounts for most regional demand. It has one of the world's largest fitness-club markets and a strong aesthetic-medicine sector that uses composition scans for client programs. Argentina's demand centers on sports nutrition and clinical dietetics, though currency volatility delays imported capital purchases. Elsewhere in the region, private hospital groups are adding analyzers to obesity and diabetes service lines.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 46.8% of regional share | High diabetes prevalence, premium wellness |
| South Africa | 6.7% CAGR (2026–2035) | Private healthcare and sports medicine |
| Rest of Middle East & Africa | USD 9.6 Million | Donor-funded nutrition programs |

GCC states lead regional spending. Diabetes prevalence there is among the highest worldwide, and premium wellness centers and national health-screening drives support analyzer purchases. South Africa's private hospital groups and sports-science institutes support steady growth. In the rest of the region, nutrition and malnutrition programs drive demand for durable, low-cost portable devices.

## Competitive Benchmarking

## Competitive Benchmarking

The Body Composition Analyzers Market is moderately concentrated. The top five vendors hold an estimated 55–65% of revenue, implying an HHI in the 900–1,100 range. InBody, Tanita, and seca lead through proprietary multi-frequency algorithms and broad regulatory clearances. Imaging leaders hold the DXA tier, and AI-driven optical start-ups fragment the consumer edge.

| Company | Est. Revenue Share Range | Key Offerings for Body Composition Analyzers Market | Strategic Positioning |
| --- | --- | --- | --- |
| InBody | ~16–20% | Multi-frequency segmental analyzers, cloud dashboards | Clinical and fitness leader with analytics lock-in |
| Tanita | ~12–15% | MC-980 Plus, consumer and professional scales | High-throughput fitness and clinical venues |
| seca | ~9–12% | mBCA medical analyzers, mBCA Alpha portable | Primary-care and hospital medical-grade focus |
| GE HealthCare | ~8–11% | Lunar iDXA and DXA software | Reference-standard imaging in research and hospitals |
| Hologic Inc. | ~7–10% | Horizon DXA systems | Bone and body-composition imaging in women's health |
| Omron Healthcare | ~5–7% | Home body composition monitors | Consumer retail and connected-health ecosystem |
| Withings | ~3–5% | Body Scan and connected smart scales | Consumer health platform with app integration |
| COSMED S.r.l. | ~2–4% | BOD POD air-displacement systems | Research and pediatric gold-standard niche |
| Bodystat Ltd | ~2–3% | Portable multi-frequency BIA, phase angle | Clinical nutrition and critical care |
| RJL Systems | ~1–2% | Quantum BIA analyzers and software | Clinical research validation |
| Fit3D | ~1–2% | 3-D optical body scanners | Fitness-club scanning and partnerships |

## Recent News & Developments

## Recent News & Developments

The Body Composition Analyzers Market saw regulatory, clinical, and investment activity over 2023–2025 that shapes purchasing through the forecast period.

- European Commission (March 2023): Adopted Regulation (EU) 2023/607, extending MDR transition deadlines and easing near-term certification pressure on analyzer manufacturers [10]
- U.S. FDA (November 2023): Approved tirzepatide for chronic weight management, broadening the patient base that needs lean-mass monitoring during therapy [24]
- CDC/NCHS (September 2024): Reported adult obesity prevalence of 40.3% for August 2021–August 2023, reinforcing U.S. clinical demand [6]
- CMS (November 2024): Finalized the CY2025 Physician Fee Schedule, keeping remote physiologic monitoring codes that support connected-scale programs [7]
- Neko Health (January 2025): Raised USD 260 million in Series B funding to scale camera-based body screening, signaling investor interest in optical assessment
- seca (2025): Launched the portable mBCA Alpha, extending medical-grade multi-frequency analysis into primary care [17]
- Hologic Inc. (October 2025): Agreed to be acquired by Blackstone and TPG, a deal that may reshape investment in its DXA portfolio [25]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The market covers bio-impedance, optical, densitometric, and mechanical body composition analyzers sold through medical, retail, and online channels to hospitals, sports, home, and research users. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 684.2 Million |
| Market Size in 2035 | USD 1,225.4 Million |
| CAGR (2026–2035) | 6.0% |
| Fastest Growing Segments | Home Care Settings (9.0% CAGR); Portable/Hand-held Systems (8.6% CAGR); 3-D Optical Body Scanners (7.7% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | InBody, Tanita, seca, GE HealthCare, Hologic Inc., Omron Healthcare, Withings, COSMED S.r.l., Bodystat Ltd, RJL Systems, Fit3D |
| Valuation Currency | USD Million |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should hospitals evaluate when procuring analyzers in the Body Composition Analyzers Market?**
A: Prioritize multi-frequency validation data against DXA, EMR export through HL7 FHIR, and documented cybersecurity testing. Total cost should include electrode consumables and software licenses, not just hardware [23].

**Q: How does 3-D optical scanning compare with impedance analysis?**
A: Optical scanning captures external shape and circumference well but infers internal composition indirectly. Impedance measures body water compartments directly, so clinicians still prefer it for fluid management [5].

**Q: Which emerging use case could reshape the Body Composition Analyzers Market?**
A: Phase-angle monitoring in oncology is gaining ground as a prognostic marker of malnutrition. Validated software for chemotherapy nutrition planning could open budgets outside dietetics departments [5].

**Q: Do consumer smart scales require FDA clearance?**
A: Most body fat analyzers fall under a Class II classification exempt from premarket notification. Clinical claims, such as fluid-overload diagnosis, can still trigger stricter review [8].

**Q: What integration challenge slows home-monitoring programs?**
A: Many scales send data to proprietary apps rather than clinical records. Without automated EHR routing, care teams must re-enter readings, which weakens RPM billing compliance [7].

**Q: Where are investors focusing within the Body Composition Analyzers Market?**
A: Capital is flowing toward camera-based screening and software platforms rather than new hardware. Neko Health's USD 260 million raise shows investor appetite for scalable, asset-light models [21].

**Q: How does pediatric testing differ from adult assessment?**
A: Children's hydration and tissue density change with growth, so adult equations misestimate fat mass. Air-displacement plethysmography with pediatric modules is the preferred reference for infants [15].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/body-composition-analyzers-market-8473*